Vilon
Also known as: Peptídeo retinal
Molecular Identifiers
Molecular Formula
C11H21N3O5
CAS Number
45234-02-4
PubChem CID
7010502UNII
H34V7IM5ML
Molecular Weight
275.30 Da
Overview
Immunological and retinal bioregulatory dipeptide developed by the Khavinson group. The smallest bioactive peptide in its class, it modulates gene expression in immune and retinal tissues. Used in short cycles for immune support and retinal protection.
Vilon (Lys-Glu) is the smallest bioactive peptide bioregulator in the Khavinson class, with only two amino acids. Despite its minimal size, it is described as capable of modulating gene expression in immune cells and in retinal tissue, supporting lymphocyte differentiation, normalization of innate immune response, and retinal integrity. It is often combined with Crystagen in immune modulation protocols.
Outside Russia, Vilon has no regulatory approval or recognized clinical indication. It is dispensed by compounding pharmacies as off-label use in short cycles of 10 to 20 days, repeated 2 to 4 times per year, generally subcutaneously or intramuscularly. Available scientific evidence is concentrated in publications from the Russian Khavinson peptide school, with few independent human clinical trials.
Within the Khavinson family, Vilon is the dipeptide derived from the thymus/immunity line that has Thymalin as its "ancestor" and Crystagen as the tripeptide on the same axis: it is presented as the minimal expression of the school's immunoregulatory logic, and is distinguished from the others less by overall mechanism and more by its ultra-short sequence (Lys-Glu). All of this comparative literature is largely Russian and preclinical.
KE Lys-Glu Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Modulation of gene expression in immune cells
- Support for retinal tissue function and integrity
- Regulation of lymphocyte differentiation and activity
- Normalization of innate immune response
- Peptide bioregulatory effect on the immune system and retina
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Vilon found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Vilon.
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VKh, Esposito JE, Giambuzzi G, Marino A, et al.
Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals